Literature DB >> 15929701

A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1.

Palanee Ammaranond1, John Zaunders, Claudette Satchell, David van Bockel, David A Cooper, Anthony D Kelleher.   

Abstract

The immune response in HIV-infected individuals who carry HLA-B27 is characterized by an immunodominant cytotoxic T lymphocyte (CTL) response to a conserved epitope corresponding to amino acids 263-272 of HIV-1 p24 gag. The arginine at position 264 is a crucial anchor residue. Amino acid substitution at 264 from arginine (R) to glycine (G), lysine (K), or threonine (T) results in a low affinity peptide that binds to HLA-B27 inefficiently and is poorly recognized by T cells that respond to the wild-type peptide. These mutants have been characterized as CTL escape mutations. We studied the plasma virus of 20 HLA-B27 longterm nonprogressors: 14 were wild type and 6 were found to be mutant. Five of these carried known escape mutations coding for K or G at position 264. One patient demonstrated a previously undescribed R264Q mutation in 30/31 clones. This altered epitope failed to elicit an IFN-gamma response from PBMC isolated from any of four HLA-B27-positive individuals with strong responses to wild-type peptide. A peptide binding assay confirmed that the R264Q mutant peptide had 30-fold lower binding affinity to HLA-B27 compared to wild type. Therefore, the R264Q variant is a likely novel escape mutation in HLA-B27-positive individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929701     DOI: 10.1089/aid.2005.21.395

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  16 in total

1.  Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Authors:  Jonathan M Carlson; Chanson J Brumme; Eric Martin; Jennifer Listgarten; Mark A Brockman; Anh Q Le; Celia K S Chui; Laura A Cotton; David J H F Knapp; Sharon A Riddler; Richard Haubrich; George Nelson; Nico Pfeifer; Charles E Deziel; David Heckerman; Richard Apps; Mary Carrington; Simon Mallal; P Richard Harrigan; Mina John; Zabrina L Brumme
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

2.  Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals.

Authors:  Chao Wu; Damien Zanker; Sophie Valkenburg; Bee Tan; Katherine Kedzierska; Quan Ming Zou; Peter C Doherty; Weisan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-11       Impact factor: 11.205

3.  HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes.

Authors:  Florencia Pereyra; David Heckerman; Jonathan M Carlson; Carl Kadie; Damien Z Soghoian; Daniel Karel; Ariel Goldenthal; Oliver B Davis; Charles E DeZiel; Tienho Lin; Jian Peng; Alicja Piechocka; Mary Carrington; Bruce D Walker
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

4.  Preferential CTL targeting of Gag is associated with relative viral control in long-term surviving HIV-1 infected former plasma donors from China.

Authors:  Mingming Jia; Kunxue Hong; Jianping Chen; Yuhua Ruan; Zhe Wang; Bing Su; Guoliang Ren; Xiaoqing Zhang; Zhen Liu; Quanbi Zhao; Dan Li; Hong Peng; Marcus Altfeld; Bruce D Walker; Xu G Yu; Yiming Shao
Journal:  Cell Res       Date:  2012-01-31       Impact factor: 25.617

5.  Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses.

Authors:  Hayato Murakoshi; Madoka Koyanagi; Takayuki Chikata; Mohammad Arif Rahman; Nozomi Kuse; Keiko Sakai; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

6.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Authors:  Ouzama Nicholson; Fay DiCandilo; James Kublin; Xiao Sun; Erin Quirk; Michelle Miller; Glenda Gray; Jean Pape; Michael N Robertson; Devan V Mehrotra; Steven Self; Katherine Turner; Jorge Sanchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo Casimiro; Scott M Hammer For The Merck V/Hiv Vaccine Trials Network Study Team
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

7.  Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid.

Authors:  Arne Schneidewind; Mark A Brockman; John Sidney; Yaoyu E Wang; Huabiao Chen; Todd J Suscovich; Bin Li; Rahma I Adam; Rachel L Allgaier; Bianca R Mothé; Thomas Kuntzen; Cesar Oniangue-Ndza; Alicja Trocha; Xu G Yu; Christian Brander; Alessandro Sette; Bruce D Walker; Todd M Allen
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan.

Authors:  Shigeru Nomura; Noriaki Hosoya; Zabrina L Brumme; Mark A Brockman; Tadashi Kikuchi; Michiko Koga; Hitomi Nakamura; Tomohiko Koibuchi; Takeshi Fujii; Jonathan M Carlson; David Heckerman; Ai Kawana-Tachikawa; Aikichi Iwamoto; Toshiyuki Miura
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 9.  Impact of MHC class I diversity on immune control of immunodeficiency virus replication.

Authors:  Philip J R Goulder; David I Watkins
Journal:  Nat Rev Immunol       Date:  2008-08       Impact factor: 53.106

10.  HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.

Authors:  Zabrina L Brumme; Mina John; Jonathan M Carlson; Chanson J Brumme; Dennison Chan; Mark A Brockman; Luke C Swenson; Iris Tao; Sharon Szeto; Pamela Rosato; Jennifer Sela; Carl M Kadie; Nicole Frahm; Christian Brander; David W Haas; Sharon A Riddler; Richard Haubrich; Bruce D Walker; P Richard Harrigan; David Heckerman; Simon Mallal
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.